Lyra Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Lyra Therapeutics Inc LYRA.OQ reported a quarterly adjusted loss of 12 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -35 cents. The mean expectation of three analysts for the quarter was for a loss of 14 cents per share. Wall Street expected results to range from -15 cents to -11 cents per share.

• Revenue fell 65.6% to $183.00 thousand from a year ago; analysts expected $240.00 thousand.

• Lyra Therapeutics Inc's reported EPS for the quarter was a loss of 13 cents​.

• The company reported a quarterly loss of $8.55 million.

• Lyra Therapeutics Inc shares had fallen by 25.3% this quarter and lost 54.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 18.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

This summary was machine generated from LSEG data May 9 at 12:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)